- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05933824
Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of LP-98 Injection in Healthy Subjects
December 20, 2023 updated by: Shanxi Kangbao Biological Product Co., Ltd.
A Randomized, Placebo-controlled, Single-administration, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of LP-98 Injection in Healthy Subjects in a First-in-human Clinical Study
A randomized, placebo-controlled, single-administration, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of LP-98 injection in healthy subjects in a first-in-human clinical study
Study Overview
Detailed Description
The study was divided into two parts, Part A and Part B. The Part A and Part B studies were carried out separately according to the protocol flow, with the Part A study carried out first.
- Part A is set up with 5 cohorts(5mg, 10mg, 20mg, 40mg, 80mg), administration is by subcutaneous, each subject entered only one cohort to receive the drug. 4 subjects were included in cohort 1, and 8 subjects were planned to be included in each cohort 2 to 5, to observe the safety, tolerability, PK and ADA of LP-98 injection by subcutaneous.
- Part B is set up with 6 cohorts (5mg,10mg,20mg,40mg,80mg, 160mg), administration is by intravenous drip, each subject entered only one cohort to receive the drug. 4 subjects were included in cohort 1, and 8 subjects were planned to be included in each cohort 2 to 6, to observe the safety, tolerability, PK and ADA of LP-98 injection by intravenous drip.
Study Type
Interventional
Enrollment (Estimated)
80
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Fan Wang
- Phone Number: +8618534115213
- Email: wangfan3063@163.com
Study Contact Backup
- Name: xian Yu He, Doctor
- Phone Number: +8613126823610
- Email: yhe@ipb.pumc.edu.cn
Study Locations
-
-
Henan
-
Zhengzhou, Henan, China, 450000
- Recruiting
- Henan Provincial Hospital for Infectious Diseases (Zhengzhou Sixth People's Hospital)
-
Contact:
- Shuang Li, Master
- Phone Number: 0371-60331736
- Email: li36918@163.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
Subjects must meet all of the following inclusion criteria for study entry:
- Willing to participate in the study and sign ICF with clear date;
- Aged 18 to 55 years at the screening visit, male or female;
- Body weight ≥ 50 kg for males or body weight ≥ 45 kg for females, and body mass index (BMI) within the range of 19 to 28 kg/m2 (inclusive);
- Be in good health in the PI's judgment, with no clinical significance in previous medical history, laboratory tests, physical examinations, vital signs, and ECG findings;
- All subjects and his/her partners must agree to use effective non-drug contraception (except for subjects had permanent contraception, i.e., bilateral tubal ligation or vasectomy, etc.) from 2 weeks prior to screening to 3 months after finishing the study. Females must have a negative serum human chorionic gonadotropin (hCG) test for pregnancy confirmation at screening;
- Willing to comply with the visits, treatments, laboratory tests and other study process required by the protocol.
Exclusion Criteria:
- Allergic to the IP or its excipients, or medicine of the same class , or having a history of severe allergies (including any food allergy or drug allergy);
- With history or family history of psychiatric, or history of chronic or serious disorders of the central nervous system, cardiovascular, hepatic, nephrological, pulmanory, digestive, metabolic, hematological or skeletal system etc., or definitive history of myelosuppression, orany other significant history of disease that may affect the safety or PK parameters in the PI's judgment;
- Having positive result for human immunodeficiency virus antibody (HIV-Ab), hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV-Ab), or Treponema pallidum antibody;
- Having clinically significant abnormal results of vital signs or laboratory tests required by the protocol;
- Having clinically significant abnormality of 12-lead ECG, or having a QTcF interval (using Fridericia's correction) > 450 ms for males or > 470 ms for females;
- With serum creatine clearance rate (Ccr) < 80 ml/min/1.73 m2 (based on Cockcroft-Gault formula);
- Known or suspected history of drug abuse (i.e., morphine, methamphetamine, ketamine, dimethylenedioxymethamphetamine, tetrahydrocannabinol acid, cocaine etc.), or having positive result for drug abuse;
- With history of heavy alcohol consumption within 1 year prior to screening (more than 21 units of alcohol per week, i.e., 360 ml of 5% beer, 45 ml of 40% hard liquor, 120 ml of 12% wine, or positive alcohol test;
- Smoking more than 5 cigarettes per day within 3 months prior to screening, or inability to comply with the prohibition of smoking during the study;
- Consuming amount > 6 servings of coffee, tea, cola, energy-drink, or other caffeine-containing product per day. One serving ≈ 120 mg of caffeine. Or consumed any caffeine-containing product within 24 hours prior to the dosing of the IP;
- Had received vaccination within 30 days prior to screening, or planning to receive vaccination during the study;
- Had received any prescription and non-prescription drugs, herbal remedies, or dietary supplements within 14 days prior to the dosing of the IP;
- Participated in any other clinical trial within 3 months prior to screening;
- Had received surgical operation within 3 months prior to screening, or planning to receive surgical operation during the study;
- Currently pregnant or lactating women;
- Had blood donation or blood loss over 200 mL within 3 months prior to screening, or planning to donate blood during the study;
- Cannot tolerate venipuncture blood collection and/or have a history of blood or needle sickness
- Other conditions considered to be ineligible for study entry in the PI's judgment
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: PartA:Dose level(5mg)
Part A is set up with 5 cohorts(5mg, 10mg, 20mg, 40mg, 80mg), administration is by subcutaneous, each subject entered only one cohort to receive the drug.
4 subjects were included in cohort 1, and 8 subjects were planned to be included in each cohort 2 to 5, to observe the safety, tolerability, PK and ADA of LP-98 injection by subcutaneous.
|
Part A is administration is by subcutaneous LP98/placebo,Part B is administration is by intravenous drip LP98/placebo
Other Names:
|
Experimental: PartA:Dose level(10mg)
Part A is set up with 5 cohorts(5mg, 10mg, 20mg, 40mg, 80mg), administration is by subcutaneous, each subject entered only one cohort to receive the drug.
4 subjects were included in cohort 1, and 8 subjects were planned to be included in each cohort 2 to 5, to observe the safety, tolerability, PK and ADA of LP-98 injection by subcutaneous.
|
Part A is administration is by subcutaneous LP98/placebo,Part B is administration is by intravenous drip LP98/placebo
Other Names:
|
Experimental: PartA:Dose level(20mg)
Part A is set up with 5 cohorts(5mg, 10mg, 20mg, 40mg, 80mg), administration is by subcutaneous, each subject entered only one cohort to receive the drug.
4 subjects were included in cohort 1, and 8 subjects were planned to be included in each cohort 2 to 5, to observe the safety, tolerability, PK and ADA of LP-98 injection by subcutaneous.
|
Part A is administration is by subcutaneous LP98/placebo,Part B is administration is by intravenous drip LP98/placebo
Other Names:
|
Experimental: PartA:Dose level(40mg)
Part A is set up with 5 cohorts(5mg, 10mg, 20mg, 40mg, 80mg), administration is by subcutaneous, each subject entered only one cohort to receive the drug.
4 subjects were included in cohort 1, and 8 subjects were planned to be included in each cohort 2 to 5, to observe the safety, tolerability, PK and ADA of LP-98 injection by subcutaneous.
|
Part A is administration is by subcutaneous LP98/placebo,Part B is administration is by intravenous drip LP98/placebo
Other Names:
|
Experimental: PartA:Dose level(80mg)
Part A is set up with 5 cohorts(5mg, 10mg, 20mg, 40mg, 80mg), administration is by subcutaneous, each subject entered only one cohort to receive the drug.
4 subjects were included in cohort 1, and 8 subjects were planned to be included in each cohort 2 to 5, to observe the safety, tolerability, PK and ADA of LP-98 injection by subcutaneous.
|
Part A is administration is by subcutaneous LP98/placebo,Part B is administration is by intravenous drip LP98/placebo
Other Names:
|
Experimental: PartB:Dose level(5mg)
Part B is set up with 6 cohorts (5mg,10mg,20mg,40mg,80mg, 160mg), administration is by intravenous drip, each subject entered only one cohort to receive the drug.
4 subjects were included in cohort 1, and 8 subjects were planned to be included in each cohort 2 to 6, to observe the safety, tolerability, PK and ADA of LP-98 injection by intravenous drip.
|
Part A is administration is by subcutaneous LP98/placebo,Part B is administration is by intravenous drip LP98/placebo
Other Names:
|
Experimental: PartB:Dose level(10mg)
Part B is set up with 6 cohorts (5mg,10mg,20mg,40mg,80mg, 160mg), administration is by intravenous drip, each subject entered only one cohort to receive the drug.
4 subjects were included in cohort 1, and 8 subjects were planned to be included in each cohort 2 to 6, to observe the safety, tolerability, PK and ADA of LP-98 injection by intravenous drip.
|
Part A is administration is by subcutaneous LP98/placebo,Part B is administration is by intravenous drip LP98/placebo
Other Names:
|
Experimental: PartB:Dose level(20mg)
Part B is set up with 6 cohorts (5mg,10mg,20mg,40mg,80mg, 160mg), administration is by intravenous drip, each subject entered only one cohort to receive the drug.
4 subjects were included in cohort 1, and 8 subjects were planned to be included in each cohort 2 to 6, to observe the safety, tolerability, PK and ADA of LP-98 injection by intravenous drip.
|
Part A is administration is by subcutaneous LP98/placebo,Part B is administration is by intravenous drip LP98/placebo
Other Names:
|
Experimental: PartB:Dose level(40mg)
Part B is set up with 6 cohorts (5mg,10mg,20mg,40mg,80mg, 160mg), administration is by intravenous drip, each subject entered only one cohort to receive the drug.
4 subjects were included in cohort 1, and 8 subjects were planned to be included in each cohort 2 to 6, to observe the safety, tolerability, PK and ADA of LP-98 injection by intravenous drip.
|
Part A is administration is by subcutaneous LP98/placebo,Part B is administration is by intravenous drip LP98/placebo
Other Names:
|
Experimental: PartB:Dose level(80mg)
Part B is set up with 6 cohorts (5mg,10mg,20mg,40mg,80mg, 160mg), administration is by intravenous drip, each subject entered only one cohort to receive the drug.
4 subjects were included in cohort 1, and 8 subjects were planned to be included in each cohort 2 to 6, to observe the safety, tolerability, PK and ADA of LP-98 injection by intravenous drip.
|
Part A is administration is by subcutaneous LP98/placebo,Part B is administration is by intravenous drip LP98/placebo
Other Names:
|
Experimental: PartB:Dose level(160mg)
Part B is set up with 6 cohorts (5mg,10mg,20mg,40mg,80mg, 160mg), administration is by intravenous drip, each subject entered only one cohort to receive the drug.
4 subjects were included in cohort 1, and 8 subjects were planned to be included in each cohort 2 to 6, to observe the safety, tolerability, PK and ADA of LP-98 injection by intravenous drip.
|
Part A is administration is by subcutaneous LP98/placebo,Part B is administration is by intravenous drip LP98/placebo
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes from baseline in respiration rate of Vital Signs
Time Frame: Within 36 days after the first administration.
|
Respiration rate in times / minute
|
Within 36 days after the first administration.
|
Changes from baseline in blood pressure of Vital Signs.
Time Frame: Within 36 days after the first administration.
|
Blood pressure in mmHg
|
Within 36 days after the first administration.
|
Changes from baseline in body temperature of Vital Signs.
Time Frame: Within 36 days after the first administration.
|
Body temperature in Celsius degree
|
Within 36 days after the first administration.
|
Changes from baseline in ECG PR intervalThe cardiac rhythm is showed in 12 Leads
Time Frame: within 36 days after administration
|
Ambulatory Electrocardiogram in the form of continuous curve.
Changes of this continuous curve will be recorded.
|
within 36 days after administration
|
Changes from baseline in ECG QRS intervalThe cardiac rhythm is showed in 12 Leads
Time Frame: within 36 days after administration
|
Ambulatory Electrocardiogram in the form of continuous curve.
Changes of this continuous curve will be recorded.
|
within 36 days after administration
|
Changes from baseline in ECG QT intervalThe cardiac rhythm is showed in 12 Leads
Time Frame: within 36 days after administration
|
Ambulatory Electrocardiogram in the form of continuous curve.
Changes of this continuous curve will be recorded.
|
within 36 days after administration
|
Changes from baseline in Blood lactate of Laboratory Examination.
Time Frame: within 36 days after administration
|
Changes of blood lactate will be recorded.
|
within 36 days after administration
|
Changes from baseline in Pregnancy test of Laboratory Examination.
Time Frame: within 36 days after administration
|
Pregnancy test will be tested in female subjects.
|
within 36 days after administration
|
Changes from baseline in red blood cell count of Laboratory Examination.
Time Frame: within 36 days after administration
|
Red blood cell count in whole blood is reported in the form of number.
|
within 36 days after administration
|
Changes from baseline in white blood cell count of Laboratory Examination.
Time Frame: within 36 days after administration
|
White blood cell count in whole blood is reported in the form of number.
|
within 36 days after administration
|
Changes from baseline in neutrophil count of Laboratory Examination.
Time Frame: within 36 days after administration
|
Neutrophil count in whole blood is reported in the form of number.
|
within 36 days after administration
|
Changes from baseline in lymphocyte count of Laboratory Examination.
Time Frame: within 36 days after administration
|
Lymphocyte count in whole blood is reported in the form of number.
|
within 36 days after administration
|
Changes from baseline in platelet count of Laboratory Examination.
Time Frame: within 36 days after administration
|
Platelet count in whole blood is reported in the form of number.
|
within 36 days after administration
|
Changes from baseline in hemoglobin of Laboratory Examination.
Time Frame: within 36 days after administration
|
Changes of hemoglobin concentration(g/dL)in whole blood will be recorded.
|
within 36 days after administration
|
Changes from baseline in PT of Laboratory Examination.
Time Frame: within 36 days after administration
|
Prothrombin time (PT) is a screening test for exogenous coagulation factors.
|
within 36 days after administration
|
Changes from baseline in INR of Laboratory Examination.
Time Frame: within 36 days after administration
|
International standardized ratio (INR) is calculated from prothrombin time and international sensitivity index (ISI) of the reagent.
|
within 36 days after administration
|
Changes from baseline in APTT of Laboratory Examination.
Time Frame: within 36 days after administration
|
Changes of total bilirubin concentration (μmol/L) in serum will be recorded.
|
within 36 days after administration
|
Changes from baseline in direct bilirubin of Laboratory Examination.
Time Frame: within 36 days after administration
|
Changes of direct bilirubin concentration (μmol/L) in serum will be recorded.
|
within 36 days after administration
|
Changes from baseline in ALT of Laboratory Examination.
Time Frame: within 36 days after administration
|
Changes of ALT concentration (U/L) in serum will be recorded.
|
within 36 days after administration
|
Changes from baseline in AST of Laboratory Examination.
Time Frame: within 36 days after administration
|
Changes of AST concentration (U/L) in serum will be recorded.
|
within 36 days after administration
|
Changes from baseline in total protein of Laboratory Examination.
Time Frame: within 36 days after administration
|
Changes of total protein concentration (g/L) in serum will be recorded.
|
within 36 days after administration
|
Changes from baseline in albumin of Laboratory Examination.
Time Frame: within 36 days after administration
|
Changes of albumin concentration (g/L) in serum will be recorded.
|
within 36 days after administration
|
Changes from baseline in creatinine of Laboratory Examination.
Time Frame: within 36 days after administration
|
Changes of creatinine concentration (μmol/L) in serum will be recorded.
|
within 36 days after administration
|
Changes from baseline in glucose of Laboratory Examination
Time Frame: within 36 days after administration
|
Changes of glucose concentration (mmol/L) in serum will be recorded.
|
within 36 days after administration
|
Changes from baseline in potassium of Laboratory Examination.
Time Frame: within 36 days after administration
|
Changes of potassium concentration (mmol/L) in serum will be recorded.
|
within 36 days after administration
|
Changes from baseline in sodium of Laboratory Examination.
Time Frame: within 36 days after administration
|
Changes of sodium concentration (mmol/L) in serum will be recorded.
|
within 36 days after administration
|
Changes from baseline in chlorine of Laboratory Examination.
Time Frame: within 36 days after administration
|
Changes of chlorine concentration (mmol/L) in serum will be recorded.
|
within 36 days after administration
|
Changes from baseline in urine specific gravity of Laboratory Examination.
Time Frame: within 36 days after administration
|
Changes of urine specific gravity will be recorded.
|
within 36 days after administration
|
Changes from baseline in urine pH of Laboratory Examination.
Time Frame: within 36 days after administration
|
Changes of urine pH value will be recorded.
|
within 36 days after administration
|
Changes from baseline in urine glucose of Laboratory Examination.
Time Frame: within 36 days after administration
|
Changes of urine glucose will be examined by qualitative test (positive or negative).
|
within 36 days after administration
|
Changes from baseline in urine protein of Laboratory Examination.
Time Frame: within 36 days after administration
|
Changes of urine protein will be examined by qualitative test (positive or negative).
|
within 36 days after administration
|
Changes from baseline in urine ketone body of Laboratory Examination.
Time Frame: within 36 days after administration
|
Changes of urine ketone body will be examined by qualitative test (positive or negative).
|
within 36 days after administration
|
Changes from baseline in urine white blood cell of Laboratory Examination.
Time Frame: within 36 days after administration
|
Changes of white blood cell in urine will be examined by qualitative test (positive or negative).
|
within 36 days after administration
|
Changes from baseline in urine occult blood of Laboratory Examination.
Time Frame: within 36 days after administration
|
Changes of urine occult blood will be examined by qualitative test (positive or negative).
|
within 36 days after administration
|
Changes from baseline in CK of Laboratory Examination
Time Frame: within 36 days after administration
|
Changes of CK concentration (U/L) in serum will be recorded.
|
within 36 days after administration
|
Changes from baseline in CK-MB of Laboratory Examination
Time Frame: within 36 days after administration
|
Changes of CK-MB concentration (ng/mL) in serum will be recorded.
|
within 36 days after administration
|
Changes from baseline in LDH of Laboratory Examination
Time Frame: within 36 days after administration
|
Changes of LDH concentration (U/L) in serum will be recorded.
|
within 36 days after administration
|
Changes from baseline in ALP of Laboratory Examination
Time Frame: within 36 days after administration
|
Changes of ALP concentration (U/L) in serum will be recorded.
|
within 36 days after administration
|
Changes from baseline in Triglyceride of Laboratory Examination
Time Frame: within 36 days after administration
|
Changes of Triglyceride concentration (mmol/L) in serum will be recorded.
|
within 36 days after administration
|
Changes from baseline in CHOL of Laboratory Examination
Time Frame: within 36 days after administration
|
Changes of CHOL concentration (mmol/L) in serum will be recorded.
|
within 36 days after administration
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes from baseline in Immunogenic blood collection of Laboratory Examination.
Time Frame: within 36 days after administration
|
Changes of immunogenic blood collection will be recorded.The historical changes of test results (including positive rate and titer) of various indicators were counted.
|
within 36 days after administration
|
Pharmacokinetics:Cmax
Time Frame: within 36 days after administration
|
pharmacokinetic characteristics of Lipovirtide in infected patients:Cmax
|
within 36 days after administration
|
Pharmacokinetics:AUC0-t
Time Frame: within 36 days after administration
|
pharmacokinetic characteristics of Lipovirtide in infected patients:AUC0-t
|
within 36 days after administration
|
Pharmacokinetics:AUC0-∞
Time Frame: within 36 days after administration
|
pharmacokinetic characteristics of Lipovirtide in infected patients:AUC0-∞
|
within 36 days after administration
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Explore changes in biomarkers (CD4+, CD8+T cell counts) from baseline after administration
Time Frame: within 36 days after administration
|
Changes of CD4+T cell counts will be recorded.
|
within 36 days after administration
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Shuang Li, Master, Henan Provincial Hospital for Infectious Diseases (Zhengzhou Sixth People's Hospital)
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 13, 2023
Primary Completion (Estimated)
December 13, 2023
Study Completion (Estimated)
December 30, 2023
Study Registration Dates
First Submitted
June 27, 2023
First Submitted That Met QC Criteria
June 27, 2023
First Posted (Actual)
July 6, 2023
Study Record Updates
Last Update Posted (Actual)
December 22, 2023
Last Update Submitted That Met QC Criteria
December 20, 2023
Last Verified
December 1, 2023
More Information
Terms related to this study
Other Study ID Numbers
- KB_LP-98_101
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hiv
-
University of Alabama at BirminghamMobile County Health Deparment; Alabama Department of Public HealthRecruitingHIV | HIV Testing | HIV Linkage to Care | HIV TreatmentUnited States
-
ANRS, Emerging Infectious DiseasesHopital Universitaire Robert-Debre; Institut de Recherche pour le Developpement and other collaboratorsUnknownHIV | HIV-uninfected Children | Children Exposed to HIVCameroon
-
French National Agency for Research on AIDS and...Elizabeth Glaser Pediatric AIDS FoundationCompletedPartner HIV Testing | Couple HIV Counseling | Couple Communication | HIV IncidenceCameroon, Dominican Republic, Georgia, India
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
CDC FoundationGilead SciencesUnknownHIV Preexposure Prophylaxis | HIV ChemoprophylaxisUnited States
-
Africa Health Research InstituteLondon School of Hygiene and Tropical Medicine; University College, London; University... and other collaboratorsRecruiting
-
Massachusetts General HospitalNational Institute of Mental Health (NIMH); Fenway Community Health; Tuberculosis...CompletedHIV/STI Risk | HIV/STI IncidenceUnited States, India
-
Hospital Clinic of BarcelonaCompletedIntegrase Inhibitors, HIV; HIV PROTEASE INHIBSpain
-
Erasmus Medical CenterNot yet recruitingHIV Infections | Hiv | HIV-1-infection | HIV I InfectionNetherlands
-
University of WashingtonNational Institute of Mental Health (NIMH)RecruitingHIV Prevention | HIV Preexposure Prophylaxis | ImplementationKenya
Clinical Trials on LP-98 injection
-
NCIC Clinical Trials GroupCompletedUnspecified Adult Solid Tumor, Protocol SpecificUnited States, Canada
-
Longbio PharmaActive, not recruitingMyelodysplastic Syndrome (MDS)China
-
Longbio PharmaRecruitingSeasonal Allergic RhinitisChina
-
Abbott Medical DevicesTerminatedAtrial Fibrillation | Coronary Arteriosclerosis | Coronary Artery Bypass Graft SurgeryCanada, United Kingdom, Netherlands, Norway, Finland, Germany
-
Longbio PharmaRecruitingParoxysmal Nocturnal Hemoglobinuria (PNH)China
-
Longbio PharmaActive, not recruitingChronic Spontaneous UrticariaChina
-
Newave Pharmaceutical IncRecruitingFollicular Lymphoma | Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Hairy Cell Leukemia | CLL/SLLUnited States
-
Centre Hospitalier Universitaire de NiceCompletedHematological MalignanciesFrance
-
Lipella Pharmaceuticals, Inc.William Beaumont HospitalsCompletedInterstitial CystitisUnited States
-
jingxueRecruitingPancreatic Carcinoma; Lipoprotein a; Overall Survival; PrognosisChina